| MRP | : |
|
| Price | : | ₹105,000.00 |
| You Save | : | ₹12,187.50 (10.4%) |
1 Vial(s)
Zytorvi 240mg Injection contains Toripalimab as its active ingredient. This monoclonal antibody is utilized for treating metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It is given as a first-line treatment alongside cisplatin and gemcitabine for adult patients, and as a standalone therapy for those with recurrent, unresectable, or metastatic NPC that has progressed following platinum-based chemotherapy.
Zytorvi 240mg Injection functions by inhibiting the PD-1 receptor, which prevents its interaction with the PD-L1 and PD-L2 ligands. This mechanism alleviates the suppression on T cells, enhancing their activity and improving immune surveillance, thereby fostering an anti-tumour immune response. In preclinical studies, the blockade of PD-1 showed a decrease in tumour growth.
Common side effects associated with Zytorvi 240mg Injection include nausea and vomiting, sensations of burning or tingling in the feet and toes, reduced appetite, diarrhoea, and constipation. It also carries warnings regarding severe immune-mediated adverse reactions that may impact any organ or tissue and could potentially be life-threatening. Such reactions can manifest at any point during treatment or even after it has been stopped, necessitating vigilant monitoring and prompt medical attention when required.
Additionally, infusion-related reactions like hypersensitivity and anaphylaxis may arise during administration. For patients who have had or are currently undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Zytorvi 240mg Injection may result in serious complications, including graft-versus-host disease (GVHD) and other transplant-related concerns. Furthermore, Zytorvi 240mg Injection is contraindicated in pregnancy due to the risk of harm to the fetus, which may include the possibility of fetal death.
The uses of Zytorvi 240mg Injection are:
Zytorvi 240mg Injection inhibits the PD-1 receptor, stopping it from interacting with the PD-L1 and PD-L2 ligands. This mechanism activates T cells, boosting their function and reinstating immune surveillance to foster an anti-tumour immune response. In preclinical studies, the inhibition of PD-1 activity led to a decrease in tumour growth.
It is crucial to notify your healthcare provider about every medication you are currently using, which includes prescription medications, over-the-counter drugs, nutritional supplements, and herbal products.
Certain medications might interact with Zytorvi 240mg Injection, possibly impacting their efficacy or leading to side effects.
Your healthcare provider delivers Zytorvi 240mg Injection via an intravenous (IV) line into your vein over a period of 30 to 60 minutes. Typically, it is administered every two to three weeks as an IV infusion. Your healthcare provider will determine the necessary number of treatments and will monitor your blood for any possible side effects. If you happen to miss an appointment, please reach out to your healthcare provider right away to arrange a new appointment.
Common side effects of Zytorvi 240mg Injection are:
Serious side effects of Zytorvi 240mg Injection are:
Zytorvi 240mg Injection has the potential to trigger severe and possibly life-threatening immune-mediated reactions, which can impact any organ and may arise at any point during treatment or after stopping the medication, necessitating careful monitoring.
It can also lead to infusion-related reactions, such as severe hypersensitivity or anaphylaxis.
Patients who are undergoing or considering HSCT should be informed about possible complications, including graft-versus-host disease.
Moreover, Zytorvi 240mg Injection poses risks to a developing fetus, making it essential to avoid use during pregnancy.
Always adhere to your healthcare provider’s guidance and participate in regular check-ups to mitigate any risks.
Molecule Name: Toripalimab
Therapeutic Class: Immunotherapy
Pharmacological Class: Monoclonal antibody
Indications:
1. First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) with cisplatin and gemcitabine.
2. Single-agent treatment for adults with recurrent, unresectable, or metastatic NPC after platinum-based chemotherapy.
At Medfast, we’re dedicated to bringing you accurate, trustworthy, and expert-vetted health information. Our primary goal is to ensure you receive content that you can rely on.
It’s crucial to understand that everything on this website is for general information purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment. We can’t stress enough the importance of consulting with your own doctor. They are the only ones who can provide tailored advice for your specific health concerns or medication questions.
Please, never ignore or delay seeking professional medical advice because of something you’ve read here. Our fundamental mission is to support and enhance the doctor-patient relationship, not to replace it.
No related products found.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.
